| Model Number |
990700.SPE |
| Medical Device Problem Code |
Adverse Event Without Identified Device or Use Problem (2993)
|
| Health Effect - Clinical Codes |
Pain (1994); Radiation Sickness Syndrome (2256); Liver Failure (4492)
|
| Date of Event |
10/25/2020
|
|
Type of Reportable Event
|
Death
|
|
Additional Manufacturer Narrative
|
|
Medical assessment from the manufacturer noted that all patients presenting with grade 3 adverse events received sequential bilobar treatment, and commented on the infrequent rate of reported grade 3 adverse events (3 out of 32 patients).Reild, pain and worsening liver function are all anticipated adverse events associated with the use of therasphere.The medical assessment concurred with the reporter's assessment of the radioembolization-induced liver disease (reild) that resulted in the patients death.The medical assessment noted that the event was likely caused from a combination of receiving therasphere to the whole liver, along with any chemotherapy the patient had received prior to therasphere treatment.
|
| |
|
Event or Problem Description
|
|
The meeting abstract titled: "yttrium-90 glass microsphere transarterial radioembolization for patients with unresectable liver-dominant breast cancer metastasis " by rishi et al.Described the results of a single-centre, retrospective review of 32 breast cancer patients treated with therasphere for liver-metastases.Adverse events were classified using the ctcae classification system (v5.0).The article reported pain (2 patients) and worsening liver-function (1 patient).One additional patient died from radioembolization-induced liver disease within 30 days of therasphere treatment.
|
| |
|
Search Alerts/Recalls
|